Cargando…

Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease

BACKGROUND: Left atrial (LA) function is an important determinant of the left ventricular (LV) filling, playing a key role in maintaining optimal cardiac performance. Pimobendan is a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. The present study aims to investigat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarcinella, Fabio, Neves, Joao, Maddox, Thomas W., Hodgkiss-Geere, Hannah M., Bode, Elizabeth F., Dukes-McEwan, Joanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Faculty of Veterinary Medicine 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971367/ https://www.ncbi.nlm.nih.gov/pubmed/32042661 http://dx.doi.org/10.4314/ovj.v9i4.16

Ejemplares similares

Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease
por: McManamey, Anna K., et al.
Publicado: (2023)

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial
por: Boswood, A., et al.
Publicado: (2016)

Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study
por: Boswood, A., et al.
Publicado: (2017)

Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs
por: Pirintr, Prapawadee, et al.
Publicado: (2023)

Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs
por: Nakamura, K., et al.
Publicado: (2017)

Radiographic quantification of left atrial size in dogs with myxomatous mitral valve disease
por: Lam, Christopher, et al.
Publicado: (2021)

Left Atrial Mural Thrombosis and Hemopericardium in a Dog with Myxomatous Mitral Valve Disease
por: Caivano, Domenico, et al.
Publicado: (2021)

Prevalence and risk factors for atrial fibrillation in dogs with myxomatous mitral valve disease
por: Guglielmini, Carlo, et al.
Publicado: (2020)

Reproducibility of echocardiographic indices of left atrial size in dogs with subclinical myxomatous mitral valve disease
por: Hsue, Weihow, et al.
Publicado: (2020)

Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly
por: Iwanuk, Nayeli, et al.
Publicado: (2019)

Plasmatic Dimethylarginines in Dogs With Myxomatous Mitral Valve Disease
por: Valente, Carlotta, et al.
Publicado: (2021)

Utility of radiographic measurements to predict echocardiographic left heart enlargement in dogs with preclinical myxomatous mitral valve disease
por: Poad, Megan H., et al.
Publicado: (2020)

Echocardiographic predictors of first onset of atrial fibrillation in dogs with myxomatous mitral valve disease
por: Baron Toaldo, Marco, et al.
Publicado: (2020)

Prognostic value of echocardiographic indices of left atrial morphology and function in dogs with myxomatous mitral valve disease
por: Baron Toaldo, Marco, et al.
Publicado: (2018)

The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study
por: Klein, Stephanie, et al.
Publicado: (2021)

Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs
por: Li, Qinghong, et al.
Publicado: (2019)

Myxomatous degeneration of the mitral valve
por: Neto, Felippe Lazar, et al.
Publicado: (2018)

Serum untargeted metabolomic changes in response to diet intervention in dogs with preclinical myxomatous mitral valve disease
por: Li, Qinghong, et al.
Publicado: (2020)

Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study
por: Boswood, Adrian, et al.
Publicado: (2020)

Echocardiographic estimation of left ventricular‐arterial coupling in dogs with myxomatous mitral valve disease
por: Osuga, Tatsuyuki, et al.
Publicado: (2021)

Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease
por: Kim, H.‐S., et al.
Publicado: (2016)

Assessment of heart rate turbulence in dogs with myxomatous mitral valve disease
por: dos Santos, Julio P., et al.
Publicado: (2021)

Pro-Inflammatory and Immunological Profile of Dogs with Myxomatous Mitral Valve Disease
por: Piantedosi, Diego, et al.
Publicado: (2022)

The effect of obesity and subsequent weight reduction on cardiac structure and function in dogs
por: Partington, C., et al.
Publicado: (2022)

Surgical treatment for left atrial rupture due to myxomatous mitral valve disease in three dogs: A case report
por: Yoshida, Tomohiko, et al.
Publicado: (2022)

Assessment of Left Atrial Deformation and Function by 2‐Dimensional Speckle Tracking Echocardiography in Healthy Dogs and Dogs With Myxomatous Mitral Valve Disease
por: Baron Toaldo, M., et al.
Publicado: (2017)

Mitral valvuloplasty with left atrial appendage closure and pacemaker implantation in a dog with severe myxomatous mitral valve degeneration: a case report
por: Yoshida, Tomohiko, et al.
Publicado: (2022)

Serotonin Concentrations in Platelets, Plasma, Mitral Valve Leaflet, and Left Ventricular Myocardial Tissue in Dogs with Myxomatous Mitral Valve Disease
por: Cremer, S.E., et al.
Publicado: (2014)

Effect of standard‐dose and high‐dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease
por: Kaplan, Joanna L., et al.
Publicado: (2022)

Hemodynamic Effects of Protamine Infusion in Dogs with Myxomatous Mitral Valve Disease Undergoing Mitral Valvuloplasty
por: Yoshida, Tomohiko, et al.
Publicado: (2022)

The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs
por: Vezzosi, Tommaso, et al.
Publicado: (2021)

Prevalence and Prognostic Importance of Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease
por: Borgarelli, M., et al.
Publicado: (2015)

Predictive model for the detection of pulmonary hypertension in dogs with myxomatous mitral valve disease
por: MIKAWA, Shoma, et al.
Publicado: (2014)

Reliability of symmetric dimethylarginine in dogs with myxomatous mitral valve disease as kidney biomarker
por: Savarese, Alice, et al.
Publicado: (2018)

ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs
por: Keene, Bruce W., et al.
Publicado: (2019)

Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs
por: Rešetar Maslov, Dina, et al.
Publicado: (2023)

Evaluation of progression of chronic kidney disease in dogs with myxomatous mitral valve disease
por: Yun, Hyejin, et al.
Publicado: (2023)

Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial
por: Wess, Gerhard, et al.
Publicado: (2020)

Myxomatous Mitral Valve with Prolapse and Flail Scallop
por: Fan, Jerry, et al.
Publicado: (2016)

Contractile properties of the right atrial myofilaments in patients with myxomatous mitral valve degeneration
por: Bening, Constanze, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3q0gh44t210b7vfkc55230su4t